EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Eukaryotic Elongation Factor 1A: How Small-Molecule Inhibitors Suppress Tumor Growth via Diverse Pathways

Han Zhang, Siqi Yu, Ying Wang, Shanmei Wu, Changliang Shan iD, Weicheng Zhang iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Han Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China. Hauptthemen laut MEDLINE: Peptide Elongation Factor 1, Neoplasms, Antineoplastic Agents, Small Molecule Libraries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eukaryotic elongation factor 1A (eEF1A), the second most abundant intracellular protein, not only plays a key role in peptide elongation, but is also capable of numerous moonlighting functions. Within malignant cells, eEF1A is by no means a neutral bystander but instead actively participates in oncogenic transformations via a myriad of molecular pathways. Thus far, a broad range of small-molecule inhibitors have been identified, which, despite their structural diversity, suppress tumor growth by targeting eEF1A. Interestingly, just as eEF1A enables its oncogenic potential far beyond boosting protein translation, these targeted agents disrupt this oncoprotein via multiple axes distinct from mere protein synthesis inhibition. Whereas the oncogenic mechanisms of eEF1A has been well documented, there lacks a systemic survey of the eEF1A-targeting agents in terms of their mechanisms. Accordingly, the present work aims to examine their multifaceted modes of action more than just blocking protein synthesis. By unveiling these insights, our deepened knowledge of these eEF1A-binding inhibitors will inform the development of future eEF1A-targeted drugs for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide Elongation Factor 1NeoplasmsAntineoplastic AgentsSmall Molecule LibrariesHumansAnimalsSignal TransductionCell ProliferationMolecular Targeted Therapy

Stichwörter der Autor:innen

anticancereEF1Ainhibitormechanismpathway

Substanzen

Peptide Elongation Factor 1Antineoplastic AgentsSmall Molecule LibrariesEEF1A1 protein, human

Autor:innen und Institutionen

  • College of Pharmacy, Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.

ORCID-Profile: Changliang Shan, Weicheng Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, H., Yu, S., Wang, Y., Wu, S., Shan, C., & Zhang, W. (2025). Targeting Eukaryotic Elongation Factor 1A: How Small-Molecule Inhibitors Suppress Tumor Growth via Diverse Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157331

Vancouver

Zhang H, Yu S, Wang Y, Wu S, Shan C, Zhang W. Targeting Eukaryotic Elongation Factor 1A: How Small-Molecule Inhibitors Suppress Tumor Growth via Diverse Pathways. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157331

BibTeX
@article{Zhang2025,
  author = {Zhang, Han and Yu, Siqi and Wang, Ying and Wu, Shanmei and Shan, Changliang and Zhang, Weicheng},
  title = {Targeting Eukaryotic Elongation Factor 1A: How Small-Molecule Inhibitors Suppress Tumor Growth via Diverse Pathways},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157331}
}
Kostenlos starten →